Literature DB >> 18846342

Experimental study on inhibitory effect of niacinamide on tumor necrosis factor-alpha-induced matrix degradation of annulus fibrous tissue in vitro.

Runbing Xu1, Zengwu Shao, Liming Xiong.   

Abstract

The inhibitory effect of niacinamide on tumor necrosis factor-alpha (TNF-alpha) induced annulus fibrous (AF) degradation was assessed, and the mechanism of the inhibition was investigated. Chiba's intervertebral disc (IVD) culture model was established. Forty-eight IVDs from 12 adult Japanese white rabbits were randomly divided into 4 groups (12 IVDs in each group), and various concentrations of niacinamide and TNF-alpha were added to the medium for intervention: negative control group, niacinamide control group (0.5 mg/mL niacinamide), degeneration group (10 ng/mL TNF-alpha), and treatment group (0.5 mg/mL niacinamide and 10 ng/mL TNF-alpha). After one week's culture, AFs were collected for glycosaminoglycan (GS) content measurement, safranin O-fast green staining, and immunohistochemical staining for type I, II collagen and cysteine containing aspartate specific protease-3 (Caspase-3). It was found that the GS content in treatment group was increased by about 48% as compared with degeneration group (t=16.93, P<0.001), and close to that in niacinamide control group (t=0.71, P=0.667). Safranine O-fast green staining exhibited higher staining density and better histological structure of AF in the treatment group as compared with the degeneration group. Immunohistochemical staining for both Type I and II collagen demonstrated that lamellar structure and continuity of collagen in treatment group were better reserved than in degeneration group. Positive staining rate of Caspase-3 in AFs of negative control group, niacinamide control group, degeneration group and treatment group was 3.4%, 4.3%, 17.9% and 10.3% respectively. The positive rate in treatment group was significantly lower than in degeneration group (P<0.01). It was concluded that niacinamide could effectively alleviate TNF-alpha induced destruction and synthesis inhibition of matrix ingredients in AFs. The inhibition may be related with reduction of expression of Caspase-3. Thus, niacinamide is of potential for IVD degeneration clinical treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18846342     DOI: 10.1007/s11596-008-0519-5

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  7 in total

Review 1.  Mitochondrial control of cell death.

Authors:  G Kroemer; J C Reed
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

2.  Tumor necrosis factor-alpha modulates matrix production and catabolism in nucleus pulposus tissue.

Authors:  Cheryle A Séguin; Robert M Pilliar; Peter J Roughley; Rita A Kandel
Journal:  Spine (Phila Pa 1976)       Date:  2005-09-01       Impact factor: 3.468

3.  Up-regulation of niacinamide in intervertebral disc aggrecan in vitro.

Authors:  Xiaoqian Xiong; Shuhua Yang; Zengwu Shao; Xin Liu; Zirui Zhan; Deyu Duan
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

4.  Protective effect of niacinamide on interleukin-1beta-induced annulus fibrosus type II collagen degeneration in vitro.

Authors:  Deyu Duan; Shuhua Yang; Zengwu Shao; Hong Wang; Xiaoqian Xiong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-02

5.  Biologic response of the intervertebral disc to static and dynamic compression in vitro.

Authors:  Dong-Liang Wang; Sheng-Dan Jiang; Li-Yang Dai
Journal:  Spine (Phila Pa 1976)       Date:  2007-11-01       Impact factor: 3.468

6.  A new culture system to study the metabolism of the intervertebral disc in vitro.

Authors:  K Chiba; G B Andersson; K Masuda; S Momohara; J M Williams; E J Thonar
Journal:  Spine (Phila Pa 1976)       Date:  1998-09-01       Impact factor: 3.468

7.  Investigation of the role of IL-1 and TNF in matrix degradation in the intervertebral disc.

Authors:  J A Hoyland; C Le Maitre; A J Freemont
Journal:  Rheumatology (Oxford)       Date:  2008-04-08       Impact factor: 7.580

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.